Platinum resistant recurrent ovarian cancer
WebbThe mainstay of treatment for platinum-resistant ovarian cancer is single agent chemotherapy. Other treatment modalities have tested in this setting with discouraging … WebbResistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer, contributing to the high mortality-to-incidence ratio. Management of the …
Platinum resistant recurrent ovarian cancer
Did you know?
Webb10 apr. 2024 · Treatment with botensilimab plus balstilimab produced responses in patients with refractory or resistant ovarian cancer, according to results from a phase 1 … Webb27 juni 2024 · Based on criteria from the Fourth Ovarian Cancer Consensus Conference, patients are considered platinum refractory if the interval between the last dose of a …
Webb30 juli 2011 · Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge. … WebbOvarian cancer is the leading cause of death for patients with gynecologic malignancies, and the standard first-line treatment is platinum-based chemotherapy and tumor …
WebbAfter recurrence, response rates to second-line chemotherapy for platinum-sensitive patients are 30% or higher; however, patients with platinum-resistant disease have significantly lower response rates of 10%-25% to chemotherapeutic agents, such as liposomal doxorubicin, topotecan, taxanes, etoposide, and gemcitabine [ 2 ]. Webb1 maj 2014 · Purpose: In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is …
Webb4 mars 2024 · Platinum resistant means your cancer comes back within 6 months of finishing your last carboplatin treatment. Your doctor might describe your cancer as: …
WebbIntroduction: Platinum-resistant ovarian cancer (PROC) is broadly defined as disease recurrence within 6 months of completing platinum-based chemotherapy, either in the … インフラ 意味WebbDiscussion. The AVF 2949g trial was a clinical study on platinum-resistant recurrent ovarian cancer. Because GI perforation was observed in five (23.8%) of the 21 patients … paesaggio pptWebb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … インフラ整備70年講演会Webb11 jan. 2024 · Single-agent administration in an initial phase I study induced responses, although of limited duration, in patients with recurrent, platinum-resistant ovarian cancer. 14 Treatment with apatinib was most frequently associated with hand-foot syndrome, hypertension, nausea, and vomiting. インフラ意味Webb29 juni 2024 · About Platinum-Resistant Ovarian Cancer Ovarian cancer is the fifth most common cause of cancer death in women. 1 Patients whose disease returns less than six months after receiving... paesaggio poloniaWebbThis study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC). Methods: Totally, … インフラ整備70年講習会WebbBackground Therapy options for patients with recurrent, platinum-resistant ovarian cancer are limited. Cortisol contributes to chemotherapy resistance, one driver of poor outcomes, by suppressing apoptotic pathways used by cytotoxic agents. paesaggio prato